INTRODUCTORY CLINICAL PHARMACOLOGY
PREMIUM REVIEW SET 2026 PRACTICE
SOLUTION GUARANTEED PASS
◉ Dosage of the drug. Answer: A required element that must be
documented in a prescription.
◉ Route of drug administration. Answer: A required element that
must be documented in a prescription.
◉ Times of drug administration. Answer: A required element that
must be documented in a prescription.
◉ Licensed prescriber's signature. Answer: A required element that
must be documented in a prescription.
◉ Over-the-counter drugs. Answer: Another term for
nonprescription drugs that do not require a prescription.
◉ Elimination. Answer: The excretion of drugs from the body, a
pharmacokinetic activity.
,◉ Orphan Drug Program. Answer: A program that encourages the
development and marketing of products to treat rare diseases.
◉ Provisional Approval. Answer: Approval granted with a written
commitment from the drug company to formally demonstrate client
benefits.
◉ Incentives in Orphan Drug Program. Answer: Research grants,
protocol assistance, and special tax credits provided to develop
products to treat rare diseases.
◉ Exclusive Marketing Rights. Answer: 7 years of exclusive
marketing rights granted to the manufacturer if the drug is
approved.
◉ Accelerated Approval. Answer: Approval of drugs based on
preliminary evidence before formal demonstration of client benefits.
◉ Pharmacokinetic Phases. Answer: The phases of
pharmacokinetics include absorption, distribution, metabolism, and
excretion.
◉ ADME. Answer: An acronym to remember the pharmacokinetic
phases: Absorption, Distribution, Metabolism, Excretion.
,◉ Absorption. Answer: The process by which drug particles in the GI
tract are moved into the body fluids.
◉ Active Transport. Answer: A mechanism for absorption in the
gastrointestinal tract.
◉ Passive Transport. Answer: A mechanism for absorption in the
gastrointestinal tract.
◉ Pinocytosis. Answer: A mechanism for absorption in the
gastrointestinal tract.
◉ Half-life. Answer: The measure of the rate at which drugs are
removed from the body.
◉ Renal Disease Effect on Half-life. Answer: Half-life can be
decreased in clients with renal disease.
◉ Liver Disease Effect on Half-life. Answer: Liver disease can
increase half-life.
◉ Dosing Frequency. Answer: Half-life can help determine dosing
frequency.
, ◉ Change in Half-life. Answer: Half-life does not change throughout
a client's life.
◉ Anaphylactic Shock Indicators. Answer: Signs that alert the nurse
to suspect that the client is developing anaphylactic shock.
◉ Bradycardia. Answer: A condition where the heart rate is slower
than normal.
◉ Hypertension. Answer: A condition characterized by consistently
elevated blood pressure.
◉ Dyspnea. Answer: A medical term for shortness of breath or
difficulty breathing.
◉ Urticaria. Answer: A skin reaction that causes itchy welts or hives.
◉ Angioedema. Answer: A type of allergic drug reaction manifested
by swelling in the deeper layers of the skin, often affecting the
eyelids, lips, and throat.
◉ Factors altering drug response in children. Answer: Factors
include slower gastric emptying, greater surface area, less protein
binding, and less cutaneous fat.
PREMIUM REVIEW SET 2026 PRACTICE
SOLUTION GUARANTEED PASS
◉ Dosage of the drug. Answer: A required element that must be
documented in a prescription.
◉ Route of drug administration. Answer: A required element that
must be documented in a prescription.
◉ Times of drug administration. Answer: A required element that
must be documented in a prescription.
◉ Licensed prescriber's signature. Answer: A required element that
must be documented in a prescription.
◉ Over-the-counter drugs. Answer: Another term for
nonprescription drugs that do not require a prescription.
◉ Elimination. Answer: The excretion of drugs from the body, a
pharmacokinetic activity.
,◉ Orphan Drug Program. Answer: A program that encourages the
development and marketing of products to treat rare diseases.
◉ Provisional Approval. Answer: Approval granted with a written
commitment from the drug company to formally demonstrate client
benefits.
◉ Incentives in Orphan Drug Program. Answer: Research grants,
protocol assistance, and special tax credits provided to develop
products to treat rare diseases.
◉ Exclusive Marketing Rights. Answer: 7 years of exclusive
marketing rights granted to the manufacturer if the drug is
approved.
◉ Accelerated Approval. Answer: Approval of drugs based on
preliminary evidence before formal demonstration of client benefits.
◉ Pharmacokinetic Phases. Answer: The phases of
pharmacokinetics include absorption, distribution, metabolism, and
excretion.
◉ ADME. Answer: An acronym to remember the pharmacokinetic
phases: Absorption, Distribution, Metabolism, Excretion.
,◉ Absorption. Answer: The process by which drug particles in the GI
tract are moved into the body fluids.
◉ Active Transport. Answer: A mechanism for absorption in the
gastrointestinal tract.
◉ Passive Transport. Answer: A mechanism for absorption in the
gastrointestinal tract.
◉ Pinocytosis. Answer: A mechanism for absorption in the
gastrointestinal tract.
◉ Half-life. Answer: The measure of the rate at which drugs are
removed from the body.
◉ Renal Disease Effect on Half-life. Answer: Half-life can be
decreased in clients with renal disease.
◉ Liver Disease Effect on Half-life. Answer: Liver disease can
increase half-life.
◉ Dosing Frequency. Answer: Half-life can help determine dosing
frequency.
, ◉ Change in Half-life. Answer: Half-life does not change throughout
a client's life.
◉ Anaphylactic Shock Indicators. Answer: Signs that alert the nurse
to suspect that the client is developing anaphylactic shock.
◉ Bradycardia. Answer: A condition where the heart rate is slower
than normal.
◉ Hypertension. Answer: A condition characterized by consistently
elevated blood pressure.
◉ Dyspnea. Answer: A medical term for shortness of breath or
difficulty breathing.
◉ Urticaria. Answer: A skin reaction that causes itchy welts or hives.
◉ Angioedema. Answer: A type of allergic drug reaction manifested
by swelling in the deeper layers of the skin, often affecting the
eyelids, lips, and throat.
◉ Factors altering drug response in children. Answer: Factors
include slower gastric emptying, greater surface area, less protein
binding, and less cutaneous fat.
